The COVID-19 pandemic created the need for widespread availability of accurate and efficient diagnostic testing for detection of SARS-CoV-2 and antiviral antibodies in infected individuals. This session will provide updates on various assay techniques and tests for COVID-19 diagnosis. This Showcase will include a selected number of companies that are developing breakthrough testing for COVID-19.
Confirmed Presenting Companies:
Dr. Ge’s work at Apostle Inc is focused on innovations in the public health and life sciences sector. In 2018, Apostle Inc was named by BioSpace as “Top 20 Life Science Startups to Watch” and was selected into the Stanford University StartX program. Prior to co-founding Apostle, he was President of BioSciKin Co., Ltd., focusing on biomedical incubation and investment. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences where he was named by the U.K. Phacilitate as "Top 50 Most Influential People in Big Data" in 2015. Between 2008 and 2011, he was an Assistant Professor at Duke University School of Medicine, where he was also a member of U.S. NIH NHGRI Special Emphasis Panel. He and colleagues discovered the IL28B genetic variants associated with clinical response to interferon treatment, published in Nature in 2009. He completed his postdoctoral training at Duke University in 2008 and received his Ph.D. in Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004.
Apostle Inc is a biotechnology company in San Jose, CA, a provider of innovative technologies for public health including liquid biopsy and disease detection. Apostle responds to the COVID-19 pandemic with a Viral RNA Isolation System that has processed over 1 million clinical samples.
Apostle COVID-19 RNA Extraction System
This presentation illustrates the effective detection of SARS-CoV-2 using the Apostle COVID-19 Viral RNA Isolation Automation System and qRT-PCR from over 1 million samples in clinical lab settings. The proficient and consistent systems provide reliable test results contributing to COVID-19 pandemic relief.
Gerald Commissiong is President & CEO Todos Medical Ltd. (OTCQB: TOMDF), in addition to Amarantus Bioscience Holdings, Inc. and interim-CEO of Breakthrough Diagnostics, Inc., Todos’ joint venture with Amarantus. Mr. Commissiong has been responsible for Amarantus’ strategic transactions, licensing, research collaborations, mergers & acquisitions in therapeutics and diagnostics, as well as fund raising, having raised over of $50 million since inception. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.
COVID-19 Testing Showcase:
Todos Medical is a commercial in vitro diagnostics company focused on developing novel, convenient tests for the early detection of COVID-19, cancer and neurodegenerative disorders.
Tollovir: Phase II Covid-19 Antiviral Drug Candidate
Tollovir: Phase II, Antiviral 3CL-Protease Inhibitor for Hospitalized Covid-19 Patients